Saturday, July 11, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “combination”

418 pharma patents match "combination" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 418
Index total 30,257
Page 6 / 18

Quick answer

This filtered view shows 418 pharmaceutical patents matching "combination" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

418 results for “combination” · 30,257 patents in full index Clear search

  1. US 11318164

    Immunotherapeutic treatment method using an interleukin-2 receptor beta-selective agonist in combination with adoptive cell transfer therapy

    Nektar Therapeutics · Granted May 3, 2022 · Expires Apr 28, 2042

    granted

  2. US 11311581

    Combination comprising spirulina and palmitoylethanolamide and/or salts or pharmaceutically acceptable derivatives thereof and their formulations, for use in the prevention and/or in the treatment of hyperactivated tissue conditions

    AGAIN LIFE ITALIA SRL · Granted Apr 26, 2022 · Expires Apr 21, 2042

    granted

  3. US 11311574

    Methods and compositions for targeted cleavage and recombination

    Sangamo Therapeutics, Inc. · Granted Apr 26, 2022 · Expires Apr 21, 2042

    granted

  4. US 11311517

    Combination of small molecule CD-47 inhibitors with other anti-cancer agents

    Aurigene Discovery Technologies Limited · Granted Apr 26, 2022 · Expires Apr 21, 2042

    granted

  5. US 11291667

    Combination therapy involving diaryl macrocyclic compounds

    TURNING POINT THERAPEUTICS, INC. · Granted Apr 5, 2022 · Expires Mar 31, 2042

    granted

  6. US 11285194

    Combination immunotherapy approach for treatment of cancer

    Calidi Biotherapeutics, Inc. · Granted Mar 29, 2022 · Expires Mar 24, 2042

    granted

  7. US 11279768

    Anti-cancer antibodies, combination therapies, and uses thereof

    PRECISION BIOLOGICS, INC. · Granted Mar 22, 2022 · Expires Mar 17, 2042

    granted

  8. US 11266746

    Therapeutic antitumor combination of a TLR4 ligand with other treatments

    The United Slates of America, as represented by the Secretary, Department of Health and Human Services · Granted Mar 8, 2022 · Expires Mar 3, 2042

    granted

  9. US 11260050

    Combination of cotinine plus antioxidant for treatment-resistant depression and correction of astrocytes functional deficit induced by depression and other neuropathological

    United States Government as represented by the Department of Veterans Affairs · Granted Mar 1, 2022 · Expires Feb 24, 2042

    granted

  10. US 11253591

    Combination of lenalidomide and polypeptide construct, and uses thereof

    TEVA PHARMACEUTICALS AUSTRALIA PTY LTD · Granted Feb 22, 2022 · Expires Feb 17, 2042

    granted

  11. US 11246950

    Combination cancer immunotherapy with pentaaza macrocyclic ring complex

    Galera Labs, LLC · Granted Feb 15, 2022 · Expires Feb 10, 2042

    granted

  12. US 11234932

    Combination HIV therapeutic

    Aphios Corporation · Granted Feb 1, 2022 · Expires Jan 27, 2042

    granted

  13. US 11236139

    Combination immunotherapy

    The United States Government represented by the Department of Veterans Affairs · Granted Feb 1, 2022 · Expires Jan 27, 2042

    granted

  14. US 11219614

    Combination cancer therapy with pentaaza macrocyclic ring complex and ascorbate compound

    Galera Labs, LLC · Granted Jan 11, 2022 · Expires Jan 6, 2042

    granted

  15. US 11219608

    Triple combination formulation for treatment of chronic pain

    Northwestern University · Granted Jan 11, 2022 · Expires Jan 6, 2042

    granted

  16. US 11207322

    Method and composition related to combination therapy for addiction

    The Board of Regents of the University of Texas System · Granted Dec 28, 2021 · Expires Dec 23, 2041

    granted

  17. US 11202784

    Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency

    Corcept Therapeutics Incorporated · Granted Dec 21, 2021 · Expires Dec 16, 2041

    granted

  18. US 11197932

    Polymer-drug conjugates for combination anticancer therapy

    The Regents of the University of California · Granted Dec 14, 2021 · Expires Dec 9, 2041

    granted

  19. US 11197844

    Triple drug combination (metformin, simvastatin, digoxin) for targeted treatment of pancreatic cancer

    The Regents of the University of California · Granted Dec 14, 2021 · Expires Dec 9, 2041

    granted

  20. US 11191757

    Combination of pimavanserin and cytochrome P450 modulators

    ACADIA Pharmaceuticals Inc. · Granted Dec 7, 2021 · Expires Dec 2, 2041

    granted

  21. US 11186873

    Combination method for treating cancer by targeting immunoglobulin superfamily member 1 (IGSF1) and mesenchymal-epithelial transition factor (MET)

    Wellmarker Bio Co., LTD. · Granted Nov 30, 2021 · Expires Nov 25, 2041

    granted

  22. US 11179394

    Method for treating cancer using a combination of Chk1 and ATR inhibitors

    Vertex Pharmaceuticals Incorporated · Granted Nov 23, 2021 · Expires Nov 18, 2041

    granted

  23. US 11166963

    Natural combination hormone replacement formulations and therapies

    Compass Therapeutics LLC · Granted Nov 9, 2021 · Expires Nov 4, 2041

    granted

  24. US 11149253

    Small molecule compound combination for reprogramming digestive tract derived epithelial cells to endodermal stem/progenitor cells, reprogramming method and application

    INSTITUTE OF TRANSFUSION MEDICINE, ACADEMY OF MILITARY MEDICAL SCIENCES, PEOPLE'S LIBRATION ARMY OF CHINA · Granted Oct 19, 2021 · Expires Oct 14, 2041

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.